Muscle Atrophy In Patients With Chronic Obstructive Pulmonary Disease

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02284932

Enrollment

Registered

2014-11-06

Start date

2011-09-30

Completion date

2018-09-30

Last updated

2016-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

COPD, atrophy, muscle

Brief summary

Limb muscle dysfunction, characterized by atrophy and weakness, is amongst the most troublesome systemic consequences of chronic obstructive pulmonary disease (COPD) leading to poor functional status and premature mortality. One prevailing hypothesis stipulates that the deterioration in muscle structure and function during COPD results from a spillover of inflammatory mediators from the lungs to the systemic circulation and then to the muscles.

Detailed description

The investigators objective is to investigate the impact of COPD on key signaling pathways involved in the muscle atrophy. Moderate to severe COPD patients (FEV1 under 60% of predicted) and healthy controls will be recruited. All of the investigators patients will undergo a thorough baseline assessment in pulmonary capacity, muscle force and body composition. Blood sampling and biopsy of the quadriceps will be done. Key proteins of signaling intramuscular pathways involved in protein synthesis and degradation will be measured in the quadriceps.

Interventions

OTHERNo specific intervention for this study

No specific intervention for this study

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

MALE

Age

55 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* male * COPD with an FEV1 of under 60% of predicted * non-smoker * between 55 and 75 years old

Exclusion criteria

* all inflammatory disease (HIV, cancer, renal and cardiac deficiency) * hormonal dysregulation * inferior limb pathology * neuromuscular pathology * history of tobacco or alcool abuse * oxygen dependent * recent exacerbation (2 months) of the symptoms of COPD

Design outcomes

Primary

Measure	Time frame
Decrease of protein degradation in muscles of wasted COPD patients	At baseline (COPD in a stable state of the disease)

Secondary

Measure	Time frame
Increase of protein synthesis in muscles of wasted COPD patients	At baseline (COPD in a stable state of the disease)

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026